Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation | Zendy

Αlexandros Briasoulis | Zendy; Amgad Mentias | Zendy; Alexander Mazur | Zendy; Paulino Álvarez | Zendy; Enrique C. Leira | Zendy; Mary VaughanSarrazin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation

Author(s) -

Αlexandros Briasoulis,

Amgad Mentias,

Alexander Mazur,

Paulino Álvarez,

Enrique C. Leira,

Mary VaughanSarrazin

Publication year - 2021

Publication title -

cardiovascular drugs and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.108

H-Index - 69

eISSN - 1573-7241

pISSN - 0920-3206

DOI - 10.1007/s10557-020-07126-2

Subject(s) - medicine , apixaban , dabigatran , rivaroxaban , warfarin , atrial fibrillation , stroke (engine) , hazard ratio , cohort , cardiology , confidence interval , mechanical engineering , engineering

Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research